Company: RGBP
Filing Date: 2025-12-05
Form Type: 253G1
Source: 0001493152-25-026350
Chunk: 162

Company: Regen BioPharma Inc
Filing Date: 2025-12-05
Form: 253G1
Chunk 162
---
      |   |
| Common         |     | David R. Koos                                     |     |            | 27,436,799 | * |     |            |   27 | % |
|                |     | c/o Regen Biopharma, Inc.                         |     |            |            |   |     |            |      |   |
|                |     | 4700 Spring Street St 304                         |     |            |            |   |     |            |      |   |
| Common         |     | La Mesa CA 91942* Harry Lander                    |     |            |            |   |     |            |      |   |
|                |     | 131 CHEMIN OIHAN BAZTER VILLEFRANQUE 64990 France |     |            | 20,020,001 |   |     |            | 19.4 | % |
| Common         |     | All Officers and Directors as a Group             |     |            | 27,436,799 | * |     |            |   27 | % |

*includes 19 shares held by BMXP Holdings Shareholder’s Business Trust and 11 shares held by the AFN Trust and 366,651 shares held by Zander Therapeutics, Inc.

Based on 10,123,771 shares issued and outstanding

| Title of Class     |     | Name and Address of Beneficial Owner  |     | Amount        
 and Nature of 
 Beneficial    
 Ownership     |         |     | Percentage |      |   |
| Series A Preferred |     | David R. Koos                         |     |               |         |     |            | 4.08 | % |
|                    |     | c/o Regen Biopharma, Inc.             |     |               | 413,288 |     |            |      |   |
|                    |     | 4700 Spring Street St 304             |     |               |         |     |            |      |   |
| Series A Preferred |     | All Officers and Directors as a Group |     |               | 413,288 |     |            | 4.08 | % |

* Includes 11 share held by BMXP Holdings Shareholder’s Business Trust, , 366,651 shares held by Zander Therapeutics, Inc. and 7 share held by the AFN Trust.

Based on 29,338 shares outstanding

<div align='center'>122</div>

| Title of Class